1
|
Abstract
The α7-type nicotinic acetylcholine receptor is one of the most unique and interesting of all the members of the cys-loop superfamily of ligand-gated ion channels. Since it was first identified initially as a binding site for α-bungarotoxin in mammalian brain and later as a functional homomeric receptor with relatively high calcium permeability, it has been pursued as a potential therapeutic target for numerous indications, from Alzheimer disease to asthma. In this review, we discuss the history and state of the art for targeting α7 receptors, beginning with subtype-selective agonists and the basic pharmacophore for the selective activation of α7 receptors. A key feature of α7 receptors is their rapid desensitization by standard "orthosteric" agonist, and we discuss insights into the conformational landscape of α7 receptors that has been gained by the development of ligands binding to allosteric sites. Some of these sites are targeted by positive allosteric modulators that have a wide range of effects on the activation profile of the receptors. Other sites are targeted by direct allosteric agonist or antagonists. We include a perspective on the potential importance of α7 receptors for metabotropic as well as ionotropic signaling. We outline the challenges that exist for future development of drugs to target this important receptor and approaches that may be considered to address those challenges. SIGNIFICANCE STATEMENT: The α7-type nicotinic acetylcholine receptor (nAChR) is acknowledged as a potentially important therapeutic target with functional properties associated with both ionotropic and metabotropic signaling. The functional properties of α7 nAChR can be regulated in diverse ways with the variety of orthosteric and allosteric ligands described in this review.
Collapse
Affiliation(s)
- Roger L Papke
- Departments of Pharmacology and Therapeutics (R.L.P) and Chemistry (N.A.H.), University of Florida, Gainesville, FL
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (R.L.P) and Chemistry (N.A.H.), University of Florida, Gainesville, FL
| |
Collapse
|
2
|
Taylor P, Shyong YJ, Samskey N, Ho KY, Radic' Z, Fenical W, Sharpless KB, Kovarik Z, Camacho-Hernandez GA. Ligand design for human acetylcholinesterase and nicotinic acetylcholine receptors, extending beyond the conventional and canonical. J Neurochem 2021; 158:1217-1222. [PMID: 33638151 DOI: 10.1111/jnc.15335] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Revised: 01/22/2021] [Accepted: 02/21/2021] [Indexed: 12/31/2022]
Abstract
We detail here distinctive departures from lead classical cholinesterase re-activators, the pyridinium aldoximes, to achieve rapid CNS penetration and reactivation of AChE in the CNS (brain and spinal cord). Such reactivation is consistent with these non-canonical re-activators enhancing survival parameters in both mice and macaques following exposure to organophosphates. Thus, the ideal cholinesterase re-activator should show minimal toxicity, limited inhibitory activity in the absence of an organophosphate, and rapid CNS penetration, in addition to its nucleophilic potential at the target, the conjugated AChE active center. These are structural properties directed to reactivity profiles at the conjugated AChE active center, reinforced by the pharmacokinetic and tissue disposition properties of the re-activator leads. In the case of nicotinic acetylcholine receptor (nAChR) agonists and antagonists, with the many existing receptor subtypes in mammals, we prioritize subtype selectivity in their design. In contrast to nicotine and its analogues that react with panoply of AChR subtypes, the substituted di-2-picolyl amine pyrimidines possess distinctive ionization characteristics reflecting in selectivity for the orthosteric site at the α7 subtypes of receptor. Here, entry to the CNS should be prioritized for the therapeutic objectives of the nicotinic agent influencing aberrant CNS activity in development or in the sequence of CNS ageing (longevity) in mammals, along with general peripheral activities controlling inflammation.
Collapse
Affiliation(s)
- Palmer Taylor
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, CA, USA
| | - Yan-Jye Shyong
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, CA, USA
| | - Nathan Samskey
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, CA, USA
| | - Kwok-Yiu Ho
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, CA, USA
| | - Zoran Radic'
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, CA, USA
| | - William Fenical
- Scripps Institution of Oceanography, University of California, CA, USA
| | - K Barry Sharpless
- Skaggs Institute for Chemical Biology, The Scripps Research Institute, San Diego, CA, USA
| | - Zrinka Kovarik
- Institute for Medical Research and Occupational Health, Zagreb, Croatia
| | | |
Collapse
|
3
|
Camacho-Hernandez GA, Taylor P. Lessons from nature: Structural studies and drug design driven by a homologous surrogate from invertebrates, AChBP. Neuropharmacology 2020; 179:108108. [DOI: 10.1016/j.neuropharm.2020.108108] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 04/08/2020] [Accepted: 04/12/2020] [Indexed: 02/07/2023]
|
4
|
Kaczanowska K, Camacho Hernandez GA, Bendiks L, Kohs L, Cornejo-Bravo JM, Harel M, Finn MG, Taylor P. Substituted 2-Aminopyrimidines Selective for α7-Nicotinic Acetylcholine Receptor Activation and Association with Acetylcholine Binding Proteins. J Am Chem Soc 2017; 139:3676-3684. [DOI: 10.1021/jacs.6b10746] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Katarzyna Kaczanowska
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093-0650, United States,
| | - Gisela Andrea Camacho Hernandez
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093-0650, United States,
- Facultad
de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Calzada Universidad 14418, Tijuana, Baja California 22390, Mexico
| | - Larissa Bendiks
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093-0650, United States,
| | - Larissa Kohs
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093-0650, United States,
| | - Jose Manuel Cornejo-Bravo
- Facultad
de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Calzada Universidad 14418, Tijuana, Baja California 22390, Mexico
| | - Michal Harel
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093-0650, United States,
| | - M. G. Finn
- School
of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| | - Palmer Taylor
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093-0650, United States,
| |
Collapse
|
5
|
Thompson AJ, Metzger S, Lochner M, Ruepp MD. The binding orientation of epibatidine at α7 nACh receptors. Neuropharmacology 2017; 116:421-428. [PMID: 28089847 PMCID: PMC5390772 DOI: 10.1016/j.neuropharm.2017.01.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 01/09/2017] [Accepted: 01/11/2017] [Indexed: 11/30/2022]
Abstract
Epibatidine is an alkaloid toxin that binds with high affinity to nicotinic and muscarinic acetylcholine receptors, and has been extensively used as a research tool. To examine binding interactions at the nicotinic receptor, it has been co-crystallised with the structural homologue acetylcholine binding protein (AChBP; PDB ID 2BYQ), and with an AChBP chimaera (3SQ6) that shares 64% sequence identity with the α7 nACh receptor. However, the binding orientations revealed by AChBP co-crystal structures may not precisely represent their receptor homologues and experimental evidence is needed to verify the ligand poses. Here we identify potential binding site interactions between epibatidine and AChBP residues, and substitute equivalent positions in the α7 nACh receptor. The effects of these are probed by [3H]epibatidine binding following the expression α7 nACh receptor cysteine mutants in HEK 293 cells. Of the sixteen mutants created, the affinity of epibatidine was unaffected by the substitutions Q55C, L106C, L116C, T146C, D160C and S162C, reduced by C186A and C187A, increased by Q114C and S144C, and abolished by W53C, Y91C, N104C, W145C, Y184C and Y191C. These results are consistent with the predicted orientations in AChBP and suggest that epibatidine is likely to occupy a similar location at α7 nACh receptors. We speculate that steric constraints placed upon the C-5 position of the pyridine ring in 3SQ6 may account for the relatively poor affinities of epibatidine derivatives that are substituted at this position.
Collapse
Affiliation(s)
| | - Simon Metzger
- Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland
| | - Martin Lochner
- Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland; Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland
| | - Marc-David Ruepp
- Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
| |
Collapse
|
6
|
Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands. Acta Pharmacol Sin 2017; 38:146-155. [PMID: 27917874 DOI: 10.1038/aps.2016.124] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 09/20/2016] [Indexed: 12/21/2022] Open
Abstract
The homomeric α7 nicotinic receptor (α7 nAChR) is widely expressed in the human brain that could be activated to suppress neuroinflammation, oxidative stress and neuropathic pain. Consequently, a number of α7 nAChR agonists have entered clinical trials as anti-Alzheimer's or anti-psychotic therapies. However, high-resolution crystal structure of the full-length α7 receptor is thus far unavailable. Since acetylcholine-binding protein (AChBP) from Lymnaea stagnalis is most closely related to the α-subunit of nAChRs, it has been used as a template for the N-terminal domain of α-subunit of nAChR to study the molecular recognition process of nAChR-ligand interactions, and to identify ligands with potential nAChR-like activities.Here we report the discovery and optimization of novel acetylcholine-binding protein ligands through screening, structure-activity relationships and structure-based design. We manually screened in-house CNS-biased compound library in vitro and identified compound 1, a piperidine derivative, as an initial hit with moderate binding affinity against AChBP (17.2% inhibition at 100 nmol/L). During the 1st round of optimization, with compound 2 (21.5% inhibition at 100 nmol/L) as the starting point, 13 piperidine derivatives with different aryl substitutions were synthesized and assayed in vitro. No apparent correlation was demonstrated between the binding affinities and the steric or electrostatic effects of aryl substitutions for most compounds, but compound 14 showed a higher affinity (Ki=105.6 nmol/L) than nicotine (Ki=777 nmol/L). During the 2nd round of optimization, we performed molecular modeling of the putative complex of compound 14 with AChBP, and compared it with the epibatidine-AChBP complex. The results suggested that a different piperidinyl substitution might confer a better fit for epibatidine as the reference compound. Thus, compound 15 was designed and identified as a highly affinitive acetylcholine-binding protein ligand. In this study, through two rounds of optimization, compound 15 (Ki=2.8 nmol/L) has been identified as a novel, piperidine-based acetylcholine-binding protein ligand with a high affinity.
Collapse
|
7
|
Wang Y, Zhu J, Zhang L. Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry. J Med Chem 2016; 60:263-272. [DOI: 10.1021/acs.jmedchem.6b01237] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Yue Wang
- School
of Chemistry and Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, China
- State
Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
| | - Jingjing Zhu
- State
Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
| | - Lianwen Zhang
- College
of Pharmacy, State Key Laboratory of Medicinal Chemical Biology and
Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China
| |
Collapse
|
8
|
Johansson JR, Beke-Somfai T, Said Stålsmeden A, Kann N. Ruthenium-Catalyzed Azide Alkyne Cycloaddition Reaction: Scope, Mechanism, and Applications. Chem Rev 2016; 116:14726-14768. [DOI: 10.1021/acs.chemrev.6b00466] [Citation(s) in RCA: 223] [Impact Index Per Article: 27.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Johan R. Johansson
- Cardiovascular
and Metabolic Diseases, Innovative Medicines and Early Development
Biotech Unit, AstraZeneca, Pepparedsleden 1, SE-43183 Mölndal, Sweden
| | - Tamás Beke-Somfai
- Research
Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok
krt. 2, H-1117 Budapest, Hungary
| | - Anna Said Stålsmeden
- Chemistry
and Biochemistry, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-41296 Göteborg, Sweden
| | - Nina Kann
- Chemistry
and Biochemistry, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-41296 Göteborg, Sweden
| |
Collapse
|
9
|
Jaikhan P, Boonyarat C, Arunrungvichian K, Taylor P, Vajragupta O. Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment. Chem Biol Drug Des 2015; 87:39-56. [DOI: 10.1111/cbdd.12627] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 07/03/2015] [Accepted: 07/15/2015] [Indexed: 12/13/2022]
Affiliation(s)
- Pattaporn Jaikhan
- Center of Excellence for Innovation in Drug Design and Discovery; Faculty of Pharmacy; Mahidol University; 447 Sri-Ayudya Road Bangkok 10400 Thailand
| | - Chantana Boonyarat
- Department of Pharmaceutical Chemistry; Faculty of Pharmaceutical Science; KhonKaen University; KhonKaen 4000 Thailand
| | - Kuntarat Arunrungvichian
- Center of Excellence for Innovation in Drug Design and Discovery; Faculty of Pharmacy; Mahidol University; 447 Sri-Ayudya Road Bangkok 10400 Thailand
- Department of Pharmacology; Skaggs School of Pharmacy and Pharmaceutical Sciences; University of California; San Diego 9500 Gilman Drive La Jolla CA 92093-0657 USA
| | - Palmer Taylor
- Department of Pharmacology; Skaggs School of Pharmacy and Pharmaceutical Sciences; University of California; San Diego 9500 Gilman Drive La Jolla CA 92093-0657 USA
| | - Opa Vajragupta
- Center of Excellence for Innovation in Drug Design and Discovery; Faculty of Pharmacy; Mahidol University; 447 Sri-Ayudya Road Bangkok 10400 Thailand
| |
Collapse
|
10
|
Zhan P, Itoh Y, Suzuki T, Liu X. Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. J Med Chem 2015; 58:7611-33. [PMID: 26086931 DOI: 10.1021/acs.jmedchem.5b00229] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Peng Zhan
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P. R. China
| | - Yukihiro Itoh
- Graduate
School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-Cho, Sakyo-Ku, Kyoto 606-0823, Japan
| | - Takayoshi Suzuki
- Graduate
School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-Cho, Sakyo-Ku, Kyoto 606-0823, Japan
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Xinyong Liu
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P. R. China
| |
Collapse
|
11
|
Arunrungvichian K, Fokin VV, Vajragupta O, Taylor P. Selectivity Optimization of Substituted 1,2,3-Triazoles as α7 Nicotinic Acetylcholine Receptor Agonists. ACS Chem Neurosci 2015; 6:1317-30. [DOI: 10.1021/acschemneuro.5b00058] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Affiliation(s)
- Kuntarat Arunrungvichian
- Center
of Excellence for Innovation in Drug Design and Discovery, Faculty
of Pharmacy, Mahidol University, 447 Sri-Ayudhya Road, Bangkok 10400, Thailand
- Department
of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0650, United States
- Department
of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Valery V. Fokin
- Department
of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Opa Vajragupta
- Center
of Excellence for Innovation in Drug Design and Discovery, Faculty
of Pharmacy, Mahidol University, 447 Sri-Ayudhya Road, Bangkok 10400, Thailand
| | - Palmer Taylor
- Department
of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0650, United States
| |
Collapse
|
12
|
Biomolecular recognition of antagonists by α7 nicotinic acetylcholine receptor: Antagonistic mechanism and structure-activity relationships studies. Eur J Pharm Sci 2015; 76:119-32. [PMID: 25963024 DOI: 10.1016/j.ejps.2015.05.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 04/24/2015] [Accepted: 05/06/2015] [Indexed: 12/20/2022]
Abstract
As the key constituent of ligand-gated ion channels in the central nervous system, nicotinic acetylcholine receptors (nAChRs) and neurodegenerative diseases are strongly coupled in the human species. In recently years the developments of selective agonists by using nAChRs as the drug target have made a large progress, but the studies of selective antagonists are severely lacked. Currently these antagonists rest mainly on the extraction of partly natural products from some animals and plants; however, the production of these crude substances is quite restricted, and artificial synthesis of nAChR antagonists is still one of the completely new research fields. In the context of this manuscript, our primary objective was to comprehensively analyze the recognition patterns and the critical interaction descriptors between target α7 nAChR and a series of the novel compounds with potentially antagonistic activity by means of virtual screening, molecular docking and molecular dynamics simulation, and meanwhile these recognition reactions were also compared with the biointeraction of α7 nAChR with a commercially natural antagonist - methyllycaconitine. The results suggested clearly that there are relatively obvious differences of molecular structures between synthetic antagonists and methyllycaconitine, while the two systems have similar recognition modes on the whole. The interaction energy and the crucially noncovalent forces of the α7 nAChR-antagonists are ascertained according to the method of Molecular Mechanics/Generalized Born Surface Area. Several amino acid residues, such as B/Tyr-93, B/Lys-143, B/Trp-147, B/Tyr-188, B/Tyr-195, A/Trp-55 and A/Leu-118 played a major role in the α7 nAChR-antagonist recognition processes, in particular, residues B/Tyr-93, B/Trp-147 and B/Tyr-188 are the most important. These outcomes tally satisfactorily with the discussions of amino acid mutations. Based on the explorations of three-dimensional quantitative structure-activity relationships, the structure-antagonistic activity relationships of antagonists and the characteristics of α7 nAChR-ligand recognitions were received a reasonable summary as well. These attempts emerged herein would not only provide helpful guidance for the design of α7 nAChR antagonists, but shed new light on the subsequent researches in antagonistic mechanism.
Collapse
|
13
|
Oueis E, Sabot C, Renard PY. New insights into the kinetic target-guided synthesis of protein ligands. Chem Commun (Camb) 2015; 51:12158-69. [DOI: 10.1039/c5cc04183j] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
This review describes the recent applications of the kinetic target guided synthesis and highlights the new advances of this strategy.
Collapse
Affiliation(s)
- Emilia Oueis
- Biomedical Sciences Research Council
- University of St. Andrews
- St. Andrews KY16 9ST
- UK
| | - Cyrille Sabot
- Normandie University
- COBRA
- UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS
- Cedex
- France
| | - Pierre-Yves Renard
- Normandie University
- COBRA
- UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS
- Cedex
- France
| |
Collapse
|
14
|
Oueis E, Nachon F, Sabot C, Renard PY. First enzymatic hydrolysis/thio-Michael addition cascade route to synthesis of AChE inhibitors. Chem Commun (Camb) 2014; 50:2043-5. [DOI: 10.1039/c3cc48871c] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
15
|
Ussing CA, Hansen CP, Petersen JG, Jensen AA, Rohde LAH, Ahring PK, Nielsen EØ, Kastrup JS, Gajhede M, Frølund B, Balle T. Synthesis, Pharmacology, and Biostructural Characterization of Novel α4β2 Nicotinic Acetylcholine Receptor Agonists. J Med Chem 2013; 56:940-51. [DOI: 10.1021/jm301409f] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Christine A. Ussing
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Camilla P. Hansen
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Jette G. Petersen
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Anders A. Jensen
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Line A. H. Rohde
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
- NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup,
Denmark
| | | | | | - Jette S. Kastrup
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Michael Gajhede
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Bente Frølund
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
| | - Thomas Balle
- Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100
Copenhagen, Denmark
- Faculty of Pharmacy, Building
A15, The University of Sydney, Sydney,
NSW 2006, Australia
| |
Collapse
|
16
|
Tieu W, Soares da Costa TP, Yap MY, Keeling KL, Wilce MCJ, Wallace JC, Booker GW, Polyak SW, Abell AD. Optimising in situ click chemistry: the screening and identification of biotin protein ligase inhibitors. Chem Sci 2013. [DOI: 10.1039/c3sc51127h] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|